PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127+ and KLRG1+ CD8 T cells.

MLA

Hui, Zhenzhen, et al. “PD-1 Blockade Potentiates Neoadjuvant Chemotherapy in NSCLC via Increasing CD127+ and KLRG1+ CD8 T Cells.” NPJ Precision Oncology, vol. 7, no. 1, May 2023, pp. 1–17. EBSCOhost, https://doi.org/10.1038/s41698-023-00384-x.

APA

Hui, Z., Ren, Y., Zhang, D., Chen, Y., Yu, W., Cao, J., Liu, L., Wang, T., Xiao, S., Zheng, L., Pu, Y., Wei, F., You, J., & Ren, X. (2023). PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127+ and KLRG1+ CD8 T cells. NPJ Precision Oncology, 7(1), 1–17. https://doi.org/10.1038/s41698-023-00384-x

Chicago

Hui, Zhenzhen, Yulin Ren, Dong Zhang, Yulong Chen, Wenwen Yu, Jie Cao, Liang Liu, et al. 2023. “PD-1 Blockade Potentiates Neoadjuvant Chemotherapy in NSCLC via Increasing CD127+ and KLRG1+ CD8 T Cells.” NPJ Precision Oncology 7 (1): 1–17. doi:10.1038/s41698-023-00384-x.